Series Unknown Funded Biotechnology Startups
Among the 44 disclosed “Series Unknown” biotechnology rounds shown (6 of 50 are undisclosed), the largest disclosed entry is Definium Therapeutics’ $805M r…
Among the 44 disclosed “Series Unknown” biotechnology rounds shown (6 of 50 are undisclosed), the largest disclosed entry is Definium Therapeutics’ $805M round dated 2026-06-23, and it dwarfs the next-largest disclosed amounts ($625M at Ligand Pharmaceuticals on 2026-06-23; $259M at UniQure on 2026-06-23). The disclosed distribution also shows a clear upper band: five rounds are $200M+ between 2026-06-23 and 2026-06-29, including $250M (Nuvation Bio, 2026-06-25) and three $200M rounds (4D Molecular Therapeutics on 2026-06-29; Taysha Gene Therapies on 2026-06-24; MoonLake Immunotherapeutics on 2026-06-23).
Dates cluster tightly in late June 2026, with multiple entries on 2026-06-23 alone ($805M Definium Therapeutics, $625M Ligand Pharmaceuticals, $259M UniQure, plus $200M MoonLake Immunotherapeutics and other disclosed rounds like Isospec Analytics at $490K). Geographically, repeated hubs are also visible—New York appears three times (e.g., Definium Therapeutics on 2026-06-23 at $805M; Nuvation Bio earlier on 2026-06-25 at $250M), while Boston appears twice and Toronto appears twice—suggesting regional concentration within the short window spanning 2026-06-22 to 2026-07-14.
Most recent rounds
50 of 2,0381,988 more funded startups
This page shows the 50 most recent rounds (back to Jun 2026). The full 2,038-company history for this listing is available on a paid plan.
Unlock all 2,038 companies in this listing — full funding history, investors, and founders.
Related listings
Frequently asked
What is the largest disclosed biotech round in this “Series Unknown” set, and how does it compare to the rest?
Definium Therapeutics’ $805M round (2026-06-23) is the top disclosed amount and stands far above the next-largest disclosed entry at $625M (Ligand Pharmaceuticals, 2026-06-23). The next steps after that drop to $259M (UniQure, 2026-06-23) and then into the $200M range (including $250M on 2026-06-25 and multiple $200M rounds in 2026-06-23 to 2026-06-29).
How concentrated are rounds around late June 2026 in this table?
The date window runs from 2026-06-22 to 2026-07-14, but several largest and mid-size disclosed rounds cluster in late June. 2026-06-23 is especially dense: multiple high-disclosed entries appear that same day, including $805M (Definium Therapeutics), $625M (Ligand Pharmaceuticals), $259M (UniQure), and $200M (MoonLake Immunotherapeutics).
Which rounds act as outliers on size, including the smallest disclosed amount?
The standout upper outlier is the $805M Definium Therapeutics round (2026-06-23). On the low end, the smallest disclosed amount is $130K for Concert Bio (2026-06-29), which is materially below the mid-to-upper disclosed rounds like Isospec Analytics at $490K (2026-06-23) and Helus Pharma at $50M (2026-06-24).
Are any locations over-represented compared with the rest of this list?
New York appears three times (e.g., Definium Therapeutics in New York with $805M on 2026-06-23; Nuvation Bio in New York with $250M on 2026-06-25; and ARMR Sciences in New York on 2026-06-23, though its amount is undisclosed). Boston appears twice (e.g., Pyxis Oncology $50M on 2026-06-30; Mesoblast $50M on 2026-06-24), and Toronto appears twice (e.g., Medicenna Therapeutics $4M on 2026-06-26; Helus Pharma $50M on 2026-06-24).
What does the disclosed-vs-undisclosed mix look like across the 50 rows shown?
There are 44 disclosed rounds and 6 undisclosed rounds out of the 50 rows shown. The disclosed ranking extremes are therefore based on those 44 entries, while companies with undisclosed amounts (e.g., Hanhe Biotechnology on 2026-07-14 and Aptevo’s $2M is disclosed rather than an example) do not enter the disclosed largest/smallest comparisons.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.